ArticleRegulatory toxicology and pharmacology : RTP2026
Human vs. cells vs. machine: A comparative analysis of toxicological points of departure derived from quantitative read-across (qRAx), in vitro data, and In silico predictions.
Article in Regulatory toxicology and pharmacology : RTP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Read-across is an expert-driven new approach methodology (NAM) used to fill gaps in chemical toxicity data. While qualitative read-across is widely used, quantitative read-across (qRAx) for deriving points of departure (PODs) has received limited attention. We compared the applicability domain, consistency, and conservatism of PODs derived from qRAx, in vitro data, and in silico predictions. Specifically, we first identified 41 substances evaluated by the U.S. EPA's Provisional Peer-Reviewed Toxicity Value (PPRTV) program for qRAx-derived oral chronic PODs. For these same substances, we generated PODs using: (i) in vitro-to-in vivo extrapolation from ToxCast bioactivity; (ii) database-calibrated in silico assessment from ToxValDB; and (iii) three quantitative structure-activity relationship (QSAR) models. Success rates for generating PODs varied considerably: qRAx 83% (34/41), ToxCast 22% (9/41), ToxValDB 66% (27/41), and QSAR 46-100% (19-41/41). qRAx yielded the most conservative PODs in the largest number of cases (44-54%). Combining multiple NAMs including at least one of ToxValDB or a QSAR model results in coverage exceeding 90% and including both in a tiered approach produces PODs that are on average within one order of magnitude of qRAx-derived values. We conclude that well-calibrated in silico methods can rapidly derive PODs with defined uncertainty, supporting time-sensitive health risk decisions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.